Phesgo (pertuzumab + trastuzumab + hyaluronidase-zzxf) Patient Assistance Program
Don’t let the high cost of brand subcutaneous trastuzumab + pertuzumab disrupt your HER2-positive breast cancer treatment. We help eligible patients access Phesgo (pertuzumab + trastuzumab + hyaluronidase-zzxf subcutaneous injection) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Phesgo (pertuzumab + trastuzumab + hyaluronidase-zzxf) is FDA-approved for HER2-positive breast cancer indications matching pertuzumab + trastuzumab: neoadjuvant treatment of HER2-positive locally advanced/inflammatory/early-stage breast cancer (with chemo), adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence (with chemo), and metastatic HER2-positive breast cancer (with docetaxel). Fixed-dose subcutaneous combination of the two HER2-targeted antibodies — substitutes for separate IV infusions of pertuzumab + trastuzumab.
- Without assistance, Phesgo costs commonly run approximately $14,000–$17,000 per dose (every 3 weeks).
- Through AffordMyPrescriptions, qualifying patients can access Phesgo for a flat $69.95 per month.
- Component IV forms: pertuzumab (Perjeta — brand only) + trastuzumab (Herceptin — multiple biosimilars now available substantially cheaper: Ogivri, Kanjinti, Ontruzant, Trazimera, Herzuma). Herceptin Hylecta is trastuzumab + hyaluronidase SC for monotherapy. Other HER2-targeted therapies: T-DM1 (Kadcyla — ADC), trastuzumab deruxtecan (Enhertu — ADC, broader HER2 expression including HER2-low), lapatinib (Tykerb — generic), tucatinib (Tukysa — combined with capecitabine + trastuzumab in HER2CLIMB), neratinib (Nerlynx — adjuvant extended). HER2 testing (IHC, FISH/ISH) essential.
What is Phesgo Prescription Assistance Program?
The Phesgo Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Phesgo (used across HER2-positive breast cancer indications in combination with chemotherapy) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, medical oncology coordination, HER2 testing documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing breast cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Phesgo PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation (typically including HER2 testing results, staging, prior therapy history, and indication-specific criteria), follow up with the manufacturer’s program until approval, manage your every-3-week injection schedule, and handle annual re-certification — so you never face a gap in your Phesgo HER2-targeted therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Phesgo enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your HER2-positive breast cancer treatment.
Pharmacy Price Comparison
- Without assistance, Phesgo costs thousands of dollars per dose at oncology centers. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted breast cancer therapy accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Phesgo advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Herceptin Hylecta SC (mono) | ~$5,500/dose | SC monotherapy alt |
| Hospital oncology | ~$16,500/dose | Save substantially |
| Community oncology | ~$15,000/dose | Save substantially |
| Specialty pharmacy | ~$14,500/dose | Save substantially |
| 340B-eligible institution | ~$14,000/dose | Save substantially |
| Trastuzumab biosimilar + Perjeta | ~$14,000/dose | Biosimilar trastuzumab alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Phesgo — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Phesgo Prescription Program?
The Phesgo Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Trastuzumab biosimilars + Perjeta achieve similar combined effect at lower cost; Phesgo’s SC fixed combination simplifies administration.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Phesgo assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Phesgo is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Phesgo:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $14,000–$17,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Phesgo assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Phesgo Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Phesgo:
Phesgo is the first fixed-dose subcutaneous combination of pertuzumab + trastuzumab co-formulated with rHuPH20 hyaluronidase. 5–8 minute SC injection in thigh substitutes for the multi-hour separate IV infusions of pertuzumab (Perjeta) + trastuzumab (Herceptin) — substantially reducing chair time and infusion-day complexity for HER2-positive breast cancer patients.
How It Works:
HER2-positive breast cancer (HER2 overexpression or amplification by IHC 3+ or FISH/ISH positive) accounts for approximately 15–20% of breast cancers and is driven by HER2/ERBB2 signaling. Dual HER2 blockade with pertuzumab + trastuzumab (binding different HER2 extracellular epitopes) produces superior outcomes vs single-agent trastuzumab — established in CLEOPATRA (metastatic), APHINITY (adjuvant), and NEOSPHERE/TRYPHAENA (neoadjuvant). Trastuzumab binds HER2 domain IV — disrupting HER2 homodimer signaling and recruiting ADCC. Pertuzumab binds HER2 domain II — preventing HER2-HER3 heterodimer formation (a major driver). The two antibodies have complementary mechanisms — dual blockade more potent than either alone. SC formulation with hyaluronidase enables rapid SC administration with similar pharmacokinetics and outcomes to the IV combination.
Form and Use:
Phesgo SC injection in thigh. Loading dose: pertuzumab 1200 mg / trastuzumab 600 mg / hyaluronidase 30,000 units (15 mL injection over approximately 8 minutes). Maintenance: pertuzumab 600 mg / trastuzumab 600 mg / hyaluronidase 20,000 units (10 mL injection over approximately 5 minutes) every 3 weeks. Combined with appropriate chemotherapy (taxane for metastatic, multi-agent for neoadjuvant/adjuvant). Continue per protocol. Cardiac function (LVEF) assessment at baseline and every 3 months during therapy. Hold for symptomatic CHF or LVEF decline.
Generic Availability:
No biosimilar Phesgo. Component IV forms: pertuzumab (Perjeta — brand only) + trastuzumab (Herceptin — multiple biosimilars now available substantially cheaper: Ogivri, Kanjinti, Ontruzant, Trazimera, Herzuma). Herceptin Hylecta is trastuzumab + hyaluronidase SC monotherapy. Other HER2-targeted therapies: T-DM1 / ado-trastuzumab emtansine (Kadcyla — ADC, also for residual disease after neoadjuvant); trastuzumab deruxtecan (Enhertu — ADC, broader HER2 expression including HER2-low per DESTINY trials); lapatinib (Tykerb — generic, oral); tucatinib (Tukysa — HER2-selective TKI, in combination with capecitabine + trastuzumab in HER2CLIMB); neratinib (Nerlynx — extended adjuvant after trastuzumab). HER2 testing (IHC ± FISH/ISH) essential for diagnosis. Chemotherapy backbones: taxanes (paclitaxel, docetaxel — generic), anthracyclines (doxorubicin, epirubicin — generic), platinum (carboplatin generic), capecitabine generic, eribulin (Halaven for some), Trodelvy (sacituzumab govitecan for some HR+/HER2- and TNBC). Endocrine therapy if HR+ disease. CDK4/6 inhibitors (Ibrance generic, Kisqali, Verzenio) for HR+/HER2-positive in select scenarios. NCCN breast cancer guidelines guide selection.
Warnings:
Boxed warnings: cardiomyopathy with left ventricular ejection fraction (LVEF) decline and clinical congestive heart failure (more common with concurrent anthracyclines — monitor LVEF at baseline and every 3 months during therapy and at 6-month intervals after completion; hold for symptomatic CHF or LVEF decline below threshold), pulmonary toxicity (ARDS, pneumonitis, pulmonary infiltrates — sometimes fatal — evaluate respiratory symptoms), embryo-fetal toxicity (HER2 essential for fetal development — pregnancy testing and effective contraception during therapy and 7 months after; pregnancy registry available), infusion reactions and severe hypersensitivity reactions. Other: febrile neutropenia (with chemo backbone), diarrhea, rash, mucositis, peripheral neuropathy (with taxane), fatigue. Pre-medication and proactive antiemetics for chemo-containing regimens.
FAQ (Frequently Asked Questions)
How much does Phesgo cost without insurance?
$14,000–$17,000 per dose (every 3 weeks). Annualized cost can exceed $250,000. Trastuzumab biosimilar + Perjeta IV combinations cost similarly or somewhat less. Specialty pharmacy and Patient Assistance Programs are essential.
Is Phesgo considered chemotherapy?
No — Phesgo is targeted therapy (anti-HER2 monoclonal antibodies). Different mechanism from chemotherapy, though Phesgo is typically combined with chemotherapy (taxanes or multi-agent) for full HER2-positive breast cancer treatment effect.
What is the difference between Phesgo and separate Perjeta + Herceptin (or biosimilar) IV infusions?
Same active drugs (pertuzumab + trastuzumab). Phesgo is the fixed-dose SC combination — 5–8 minute injection vs hours-long separate IV infusions. Substantially reduces chair time. Pharmacokinetics and clinical outcomes equivalent to the IV combination per FeDeriCa trial. Generally preferred when SC route appropriate.
Why is HER2 testing required before starting Phesgo?
Phesgo (and all HER2-targeted therapies) is specifically active against HER2-positive breast cancer (HER2 IHC 3+ or FISH/ISH amplified). Tumor HER2 testing (IHC with FISH/ISH reflex if equivocal) is essential for diagnosis and treatment selection.
Why is cardiac monitoring important on Phesgo?
HER2-targeted therapies cause LVEF decline and symptomatic CHF in some patients — risk increased with concurrent or prior anthracycline chemotherapy. Baseline LVEF assessment (echocardiogram or MUGA), then every 3 months during therapy, then 6-month intervals after completion. Hold therapy for symptomatic CHF or significant LVEF decline.
Take Control of Your Medication Costs
HER2-targeted therapy for HER2-positive breast cancer should not be derailed by cost. Our Phesgo advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Phesgo through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.